GRI Bio CEO Highlights Phase 2a IPF Biomarker Gains in Fibrosis and Lung Repair
GRI Bio CEO Marc Hertz detailed additional positive Phase 2a data in idiopathic pulmonary fibrosis, highlighting biomarker improvements in key drivers of fibrosis and lung repair. The company emphasized these results during a Virtual Investor “What This Means” segment to reinforce the potential of its lead oral NKT cell modulator, GRI-0621.
1. Virtual Investor Segment Participation
GRI Bio’s President and CEO Marc Hertz participated in a Virtual Investor “What This Means” segment, presenting the company’s strategic vision and recent clinical achievements to investors and analysts.
2. Phase 2a IPF Data Highlights
Hertz reviewed additional Phase 2a data in idiopathic pulmonary fibrosis, focusing on biomarker results that demonstrated reductions in fibrotic drivers and enhancements in lung repair markers, underscoring the therapeutic potential of the NKT cell modulator.
3. Lead Program GRI-0621 Profile
GRI-0621, an RARβγ agonist designed to inhibit invariant NKT cell activity, remains the company’s flagship candidate for IPF, with oral dosing aimed at interrupting inflammatory and fibrotic pathways earlier in disease progression.
4. Pipeline and Future Outlook
Beyond IPF, GRI Bio is advancing a diverse NKT cell agonist pipeline for systemic lupus erythematosus and leveraging its library of over 500 proprietary compounds to expand into additional inflammatory and fibrotic indications.